COVID-19 Vaccine Being Developed in India to ‘Enter’ Phase 3 Trial
Biswabrata Goswami
Hummingbird News
KRISHNAGAR, 18 AUG: In a major breakthrough, India is set to begin phase 3 trials for an indigenously developed potential COVID-19 vaccine, NITI Aayog member V K Paul said on Tuesday. However, Paul did not reveal the name and details of the potential COVID-19 vaccine candidate.
“As
far as Coronavirus vaccines are concerned, Prime Minister Narendra Modi had
assured the country on Independence Day. He had said that three vaccines are
being developed in India and are in different stages. One of them will enter
phase 3 trial today or tomorrow,” Paul said during a media briefing today. The
other two experimental vaccines are in phase 1 and phase 2 clinical trials.
India has two indigenous vaccines which are undergoing human trials. These are COVXIN and ZyCoV-D. Covaxin is being developed by Bharat Biotech, Indian Council of Medical Research (ICMR), and National Institute of Virology, Pune. COVAXIN already completed phase 1 human trials in just one month. It had begun its Phase 2 human trials. Human trials of COVAXIN are going on in 12 sites across India.
Zydus
Cadila is developing the other potential COVID vaccine ZyCoV-D. Meanwhile, the
Pune-based Serum Institute is also beginning the phase 3 human trials of
Oxford-AstraZeneca’s coronavirus candidate.
Around the world, there are eight vaccine candidates that have managed to enter the phase 3 trials. These are Oxford-Astra Zeneca, Moderna, Pfizer-BioNtech, Beijing Institute of Biological Products-Sinopharm, Wuhan Institute of Biological Products-Sinopharm, Sinovac, Cansino, and Russia’s Sputnik-V. Meanwhile, Sputnik-V has been given conditional registration and China’s Cansino has received patent and approval for military use.
Courtesy: Images from iNET.
.
Most wanted thing in the world at this moment. Good report.
ReplyDeleteYes, Indian people are eagerly waiting for it. Thank you.
Delete